Health Care & Life Sciences » Biotechnology | Marina Biotech Inc.

Marina Biotech Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,115.00
500.00
-
-
-
135,068
Cost of Goods Sold (COGS) incl. D&A
-
-
-
49.20
450.90
-
Gross Income
2,115.00
-
-
49.20
450.90
-
SG&A Expense
2,480.00
4,020.00
1,107.60
708.50
5,639.70
579,072
EBIT
365.00
3,520.00
-
757.70
6,090.60
468,866
Unusual Expense
1,026.00
552.00
-
75.10
-
-
Non Operating Income/Expense
30.00
2,503.00
0.60
-
-
4,931
Interest Expense
249.00
1,006.00
-
3.50
127.90
3,096
Pretax Income
1,610.00
6,477.00
1,107.00
836.30
6,218.50
440,008
Income Tax
39.00
-
1.60
0.80
0.80
55,274
Consolidated Net Income
1,571.00
6,477.00
1,108.60
837.10
6,219.30
388,861
Net Income
1,571.00
6,477.00
1,108.60
837.10
6,219.30
388,861
Net Income After Extraordinaries
1,571.00
6,477.00
1,108.60
837.10
6,219.30
388,861
Net Income Available to Common
1,571.00
6,477.00
1,108.60
837.10
6,219.30
401,857
EPS (Basic)
0.90
2.60
3.80
0.20
0.63
4.95
Basic Shares Outstanding
1,693.80
2,463.50
291.90
4,743.10
9,836.10
81,114.20
EPS (Diluted)
0.93
2.63
3.80
0.18
0.63
4.95
Diluted Shares Outstanding
1,693.80
2,463.50
291.90
4,743.10
9,836.10
81,114.20
EBITDA
365.00
3,520.00
1,107.60
708.50
5,639.70
444,004

About Marina Biotech

View Profile
Address
200 Technology Square
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.modernatx.com
Updated 07/08/2019
Marina Biotech, Inc. is a biotechnology company, which is engages in the discovery, development, and commercialization of drug therapeutics for hypertension. It offers Perstalia, which contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension. The company was founded on September 23, 1983 and is headquartered in City of Industry, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.